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The induction of cellular senescence by activated oncogenes acts as a barrier to cell 
transformation. Now, Sun et al. (2007) identify a key component of a senescence pathway 
that prevents tumorigenesis in a mouse model of skin cancer. They show that the p38-
regulated/activated protein kinase (PRAK) induces senescence downstream of oncogenic 
Ras by directly phosphorylating and activating the tumor-suppressor protein p53.Cellular senescence suppresses the 
development of cancer by arrest-
ing the proliferation of damaged 
or stressed cells that are at risk for 
malignant transformation (Camp-
isi, 2005). Of the many stimuli that 
induce senescence, DNA damage is 
the best understood. Genomic dam-
age initiates a cascade of phosphor-
ylation events in the nucleus, which in 
turn orchestrate DNA repair or—if the 
damage is severe or irreparable—cell 
death or senescence. The pivotal inte-
grator and effector of these damage 
signals is p53, a tumor-suppressor 
protein that controls the expression 
of numerous genes (Wahl and Carr, 
2001). Activity of p53 is regulated at 
multiple levels, including degradation 
by H/MDM2, stabilization by ARF, and 
phosphorylation by the DNA-damage 
response kinases. Many activated or 
overexpressed oncogenes, especially those that deliver strong mitogenic 
signals from plasma membrane 
receptors, also trigger p53-depend-
ent senescence both in culture and in 
vivo (Braig and Schmitt, 2006). These 
oncogenes, of which (activated) Ha-
RasV12 is the prototype, also trig-
ger the mitogen-activated protein 
kinase (MAPK) pathway (Figure 1). 
In this issue, Sun et al. (2007) add a 
new dimension to oncogene-induced 
senescence. They show that PRAK, a 
downstream kinase in the MAPK sig-
naling cascade, is essential for Ras-
induced senescence and its ability to 
suppress tumorigenesis in vivo in a 
mouse model of skin cancer.
Given that the MAPK pathway is 
initiated in the cytoplasm, how do 
activated RAS and similar onco-
genes cause senescence? Recent 
findings show that these oncogenes 
cause unbalanced DNA replication Cell 128, Jaand a classic DNA-damage response 
(Bartkova et al., 2006; Di Micco et al., 
2006; Mallette et al., 2007). Although 
the mechanism is not fully under-
stood, it may be due to increased 
expression of positive regulators of S 
phase. Consequently, replicons refire 
or terminate prematurely, generating 
DNA breaks that initiate a DNA-dam-
age response and phosphorylation 
of p53 by DNA-damage response 
kinases. Components of the MAPK 
cascade also increase the expression 
of the tumor suppressor ARF and ini-
tiate a negative feedback loop that 
ultimately inhibits H/MDM2, resulting 
in p53 stabilization (Courtois-Cox et 
al., 2006) (Figure 1). Thus, oncogene-
induced senescence appears to 
operate through known mechanisms 
that converge on p53.
In their new work, Sun et al. iden-
tify a downstream component of the Figure 1. Multiple Pathways Mediate Oncogene-Induced Senescence
Oncogenes that deliver strong mitogenic signals, typified by overexpressed oncogenic RAS, 
cause cellular senescence that arrests cell proliferation. Active RAS initiates two protein kinase 
cascades: the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 
kinase (PI3K) pathway. The MAPK pathway includes the RAF and PRAK kinases and increases 
the activity of p53, a tumor suppressor and pivotal regulator of the senescence response, by two 
distinct mechanisms. First, MAPK components induce the expression of ARF, which stabilizes 
p53 by antagonizing the degradative activity of H/MDM2. Second, PRAK, a downstream MAPK 
component, directly phosphorylates and activates p53. In addition, active RAF induces the se-
nescence of some cells independent of p53 function. It is not known whether this activity of RAF 
requires PRAK or other MAPK components. The PI3K pathway stabilizes p53 through the inacti-
vation of H/MDM2. In addition to activating these kinase cascades, and possibly working through 
them, oncogenic RAS causes unbalanced DNA replication, resulting in DNA damage. The DNA-
damage response initiates yet another protein kinase cascade that activates p53, but in this case 
phosphorylation occurs on sites distinct from that phosphorylated by PRAK. Finally, reactive 
oxygen species (ROS) are an intermediary in RAS signaling and may damage DNA directly.nuary 26, 2007 ©2007 Elsevier Inc. 233
MAPK pathway, PRAK, that is impor-
tant for oncogene-induced senes-
cence. Interestingly, PRAK—unlike 
other MAPK components, such as 
RAF, immediately downstream of 
RAS—did not cause senescence 
when oncogenically activated or over-
expressed (see Courtois-Cox et al., 
2006). Rather, PRAK overexpression 
alone only slightly suppressed cell 
proliferation. However, it substantially 
enhanced RAS-induced senescence, 
increasing both the kinetics and 
robustness of the response. In fact, 
PRAK was required for the increase 
in p53 transcriptional activity that is 
stimulated by oncogenic RAS but 
not by direct DNA damage. Sun et al. 
also show that PRAK directly phos-
phorylates p53 on a residue that is 
distinct from those targeted by the 
DNA-damage response kinases.
These new findings provide insights 
into how some oncogenes engage 
the senescence program to ensure 
suppression, rather than promotion, 
of tumorigenesis. They indicate that 
oncogene-induced senescence and 
the DNA-damage response have both 
common and unique modes of action, 
and that both processes activate p53 
(Figure 1). Are there additional layers 
of complexity yet to be uncovered? 
The answer almost certainly is yes.
In many cases, including those 
discussed above, oncogene-induced 
senescence is p53 dependent. This is 
not always the case, however. Onco-
genic RAF, for example, induces 
senescence in both human fibroblasts 
and mammary epithelial cells inde-
pendent of p53 function (Olsen et al., 
2002; Zhu et al., 1998). In fibroblasts, 
oncogenic RAF increases the expres-
sion of p16INK4A (Zhu et al., 1998), a 
cyclin-dependent kinase inhibitor that 
prevents the phosphorylation and 
inactivation of the Retinoblastoma 
protein (pRB). pRB lies at the heart 
of a second major tumor-suppressor 
pathway that regulates the senes-
cence response (Campisi, 2005). In 
mammary epithelial cells, though, 
RAF induces senescence independ-
ently of both p53 and p16INK4a (Olsen 
et al., 2002). Given the well-estab-
lished and crucial role that p53 plays 
in mediating DNA-damage responses 234 Cell 128, January 26, 2007 ©2007 E(Wahl and Carr, 2001), these findings 
suggest that oncogenic RAS, but not 
oncogenic RAF, drives unbalanced 
DNA replication and the subsequent 
DNA-damage response—despite the 
fact that RAF is immediately down-
stream of RAS. Moreover, they sug-
gest that there are multiple pathways 
to the final growth-arrested senes-
cent state (Campisi, 2005).
Additionally, there may well be 
both cell type- and oncogene-spe-
cific differences in how oncogenes 
induce senescence. Moreover, each 
component of signaling cascades, 
such as those governed by RAS, 
may have unique effects not shared 
by downstream components. For 
example, RAS and similar GTPases 
generate reactive oxygen species as 
signaling molecules, which in turn 
activate or inactivate redox-sensi-
tive mediator proteins (Finkel, 2003). 
It is therefore possible that signaling 
by oncogenic RAS, but not all com-
ponents of the MAPK pathway, initi-
ates unique processes, such as the 
increased expression of genes that 
result in unbalanced DNA replica-
tion. Further, the high level of reac-
tive oxygen species produced by 
an overexpressed RAS oncogene 
might damage nuclear DNA, leading 
directly to a p53-dependent DNA-
damage response or might also 
exacerbate unbalanced DNA repli-
cation because of increased oxida-
tive lesions that can retard or stall 
replication fork progression.
Although p53 controls multiple 
responses to stress and damage, 
including the permanent senescent 
growth arrest, a transient cell-cycle 
arrest, and cell death (Wahl and Carr, 
2001), p53 is dispensable at least for 
RAF-induced senescence of mam-
mary epithelial cells (Olsen et al., 
2002). What then are the ultimate 
mechanisms that establish and main-
tain the senescent growth arrest? 
One possibility is the pRb pathway, 
which can be indirectly activated by 
p53 via transcriptional upregulation 
of the p21 cyclin-dependent kinase 
inhibitor. Although p16 INK4A does not 
appear to be required for the senes-
cence growth arrest (Campisi, 2005), 
other means of activating the pRb lsevier Inc.tumor suppressor pathway may be 
crucial. Yet, p21 is induced similarly 
whether cells undergo a transient or 
senescent growth arrest, and RAF-
induced senescence of mammary 
epithelial cells occurs even in the 
presence of viral oncogenes that 
inactivate pRb (Olsen et al., 2002). 
Thus, at this time, the available data 
cannot rule out the possibility of a 
senescence pathway that is inde-
pendent of both p53 and pRb.
The mechanisms that regulate and 
implement oncogene-induced senes-
cence, and their relationship to other 
inducers of senescence, may well be 
as myriad and complex as the data 
to date suggest (Figure 1). Under-
standing the signals and kinetics that 
establish and maintain the senescent 
growth arrest may only reveal that 
these pathways are woven in a com-
plex tapestry. However, it is equally 
possible that future experiments will 
show that these pathways converge 
on a few critical threads.
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